Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo.

Haggag YA, Matchett KB, Falconer RA, Isreb M, Jones J, Faheem A, McCarron P, El-Tanani M.

Cancers (Basel). 2019 Feb 14;11(2). pii: E222. doi: 10.3390/cancers11020222.

2.

Anti-Invasive and Anti-Proliferative Effects of shRNA-Loaded Poly(Lactide-Co-Glycolide) Nanoparticles Following RAN Silencing in MDA-MB231 Breast Cancer Cells.

Sharma A, McCarron P, Matchett K, Hawthorne S, El-Tanani M.

Pharm Res. 2018 Dec 17;36(2):26. doi: 10.1007/s11095-018-2555-6.

3.

The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer.

Dakir EH, Pickard A, Srivastava K, McCrudden CM, Gross SR, Lloyd S, Zhang SD, Margariti A, Morgan R, Rudland PS, El-Tanani M.

Oncotarget. 2018 Oct 9;9(79):34889-34910. doi: 10.18632/oncotarget.26175. eCollection 2018 Oct 9.

4.

Enhanced cutaneous wound healing in rats following topical delivery of insulin-loaded nanoparticles embedded in poly(vinyl alcohol)-borate hydrogels.

Abdelkader DH, Tambuwala MM, Mitchell CA, Osman MA, El-Gizawy SA, Faheem AM, El-Tanani M, McCarron PA.

Drug Deliv Transl Res. 2018 Oct;8(5):1053-1065. doi: 10.1007/s13346-018-0554-0.

5.

Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer.

Wong JPC, Wei R, Lyu P, Tong OLH, Zhang SD, Wen Q, Yuen HF, El-Tanani M, Kwok HF.

Int J Biol Sci. 2017 Nov 1;13(11):1373-1386. doi: 10.7150/ijbs.21457. eCollection 2017.

6.

Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells.

Alharbi RA, Pandha HS, Simpson GR, Pettengell R, Poterlowicz K, Thompson A, Harrington K, El-Tanani M, Morgan R.

Oncotarget. 2017 Aug 7;8(52):89566-89579. doi: 10.18632/oncotarget.20023. eCollection 2017 Oct 27.

7.

Targeting HOX/PBX dimers in cancer.

Morgan R, El-Tanani M, Hunter KD, Harrington KJ, Pandha HS.

Oncotarget. 2017 May 9;8(19):32322-32331. doi: 10.18632/oncotarget.15971. Review.

8.

Erythropoietin drives breast cancer progression by activation of its receptor EPOR.

Chan KK, Matchett KB, Coulter JA, Yuen HF, McCrudden CM, Zhang SD, Irwin GW, Davidson MA, Rülicke T, Schober S, Hengst L, Jaekel H, Platt-Higgins A, Rudland PS, Mills KI, Maxwell P, El-Tanani M, Lappin TR.

Oncotarget. 2017 Jun 13;8(24):38251-38263. doi: 10.18632/oncotarget.16368.

9.

Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells.

Haggag YA, Matchett KB, Dakir el-H, Buchanan P, Osman MA, Elgizawy SA, El-Tanani M, Faheem AM, McCarron PA.

Int J Pharm. 2017 Apr 15;521(1-2):40-53. doi: 10.1016/j.ijpharm.2017.02.006. Epub 2017 Feb 2.

PMID:
28163220
10.

Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling.

Yuen HF, Chan KK, Platt-Higgins A, Dakir el-H, Matchett KB, Haggag YA, Jithesh PV, Habib T, Faheem A, Dean FA, Morgan R, Rudland PS, El-Tanani M.

Oncotarget. 2016 Nov 15;7(46):75854-75864. doi: 10.18632/oncotarget.12420.

11.

Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy.

El-Tanani M, Dakir el-H, Raynor B, Morgan R.

Cancers (Basel). 2016 Mar 14;8(3). pii: E35. doi: 10.3390/cancers8030035. Review.

12.

Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from diblock copolymers of PLGA and PEG.

Haggag Y, Abdel-Wahab Y, Ojo O, Osman M, El-Gizawy S, El-Tanani M, Faheem A, McCarron P.

Int J Pharm. 2016 Feb 29;499(1-2):236-246. doi: 10.1016/j.ijpharm.2015.12.063. Epub 2015 Dec 30.

PMID:
26746800
13.

Protein deregulation associated with breast cancer metastasis.

Chan KK, Matchett KB, McEnhill PM, Dakir el H, McMullin MF, El-Tanani Y, Patterson L, Faheem A, Rudland PS, McCarron PA, El-Tanani M.

Cytokine Growth Factor Rev. 2015 Aug;26(4):415-23. doi: 10.1016/j.cytogfr.2015.05.002. Epub 2015 May 31. Review.

PMID:
26088937
14.

Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation.

Maxwell P, Melendez-Rodríguez F, Matchett KB, Aragones J, Ben-Califa N, Jaekel H, Hengst L, Lindner H, Bernardini A, Brockmeier U, Fandrey J, Grunert F, Oster HS, Mittelman M, El-Tanani M, Thiersch M, Schneider Gasser EM, Gassmann M, Dangoor D, Cuthbert RJ, Irvine A, Jordan A, Lappin T, Thompson J, Neumann D.

Br J Haematol. 2015 Feb;168(3):429-42. doi: 10.1111/bjh.13133. Epub 2014 Oct 4.

PMID:
25283956
15.

Ran GTPase in nuclear envelope formation and cancer metastasis.

Matchett KB, McFarlane S, Hamilton SE, Eltuhamy YS, Davidson MA, Murray JT, Faheem AM, El-Tanani M.

Adv Exp Med Biol. 2014;773:323-51. doi: 10.1007/978-1-4899-8032-8_15. Review.

PMID:
24563355
16.

BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.

Busacca S, Chacko AD, Klabatsa A, Arthur K, Sheaff M, Barbone D, Mutti L, Gunasekharan VK, Gorski JJ, El-Tanani M, Broaddus VC, Gaudino G, Fennell DA.

PLoS One. 2013 Jun 7;8(6):e65489. doi: 10.1371/journal.pone.0065489. Print 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/90879c69-ebc5-40b2-9926-4a00e4f9e055. Barbone, Dario [added]; Mutti, Luciano [added].

17.

RanGTPase: a candidate for Myc-mediated cancer progression.

Yuen HF, Gunasekharan VK, Chan KK, Zhang SD, Platt-Higgins A, Gately K, O'Byrne K, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

J Natl Cancer Inst. 2013 Apr 3;105(7):475-88. doi: 10.1093/jnci/djt028. Epub 2013 Mar 6.

PMID:
23468463
18.

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.

Yuen HF, Abramczyk O, Montgomery G, Chan KK, Huang YH, Sasazuki T, Shirasawa S, Gopesh S, Chan KW, Fennell D, Janne P, El-Tanani M, Murray JT.

Biosci Rep. 2012 Aug;32(4):413-22. doi: 10.1042/BSR20120050.

19.

Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression.

Yuen HF, McCrudden CM, Grills C, Zhang SD, Huang YH, Chan KK, Chan YP, Wong ML, Law S, Srivastava G, Fennell DA, Dickson G, El-Tanani M, Chan KW.

Cancer Sci. 2012 Jun;103(6):1145-54. doi: 10.1111/j.1349-7006.2012.02252.x. Epub 2012 Apr 3.

20.

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

Supplemental Content

Loading ...
Support Center